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Abstract
Pregnancies resulting from fertility treatment are associated with higher rates of multiple 
pregnancy and have higher rates of pregnancy complications than spontaneously con-
ceived pregnancies. Methods exist to make fertility treatment safer and less likely to result 
in multiple pregnancy and practitioners should be practicing fertility treatment with the 
aim to produce a healthy, term, singleton pregnancy. Approaches to minimising the risk 
of multiple pregnancy include carefully monitoring ovulation induction (OI) cycles to 
produce mono-follicular ovulation. Identifying patients at risk of excessive response to 
ovulation induction and treating them with low dose therapies and close monitoring is 
a critical step in practicing safe OI treatment. Performing single embryo transfer in all 
but exceptional cases of in-vitro fertilisation (IVF), and never transferring more than two 
embryos, is the single, most successful way to reduce the multiple pregnancy rate with 
IVF. An appreciation of the increased risk of mono-chorionic twinning with IVF is also 
important. This chapter will explore ways to minimise the risk of multiple pregnancy 
with a variety of fertility treatments.
Keywords: ART, multiple pregnancy, ovulation induction, single embryo transfer
1. Introduction
Assisted Reproductive Technology (ART) has, since its inception, been associated with 
increased rates of multiple pregnancy as the treating doctors struggled to balance an acceptable 
live birth rate with the risk of multiple pregnancy. A multiple pregnancy results in increased 
rates of both maternal and neonatal morbidity compared with a singleton pregnancy. Further, 
multiple pregnancy is associated with increased rates of prematurity, especially an increased 
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rate of severe prematurity, low birth weight, neonatal death and longer term developmental 
concerns [1]. Women with a multiple pregnancy are at risk of nearly every complication of 
pregnancy in comparison to women pregnant with a singleton pregnancy. Pre-eclampsia, 
gestational diabetes and operative delivery are all associated with significant increased 
maternal morbidity in multiple pregnancies.
A multiple pregnancy, for patients who have suffered through months or years of infertil-
ity and treatment, can often be seen as a “double blessing” and may indeed result in a suc-
cessful outcome for many patients. For many years rates of multiple pregnancy for women 
undergoing ART were accepted as a necessary part of treatment. With ongoing development 
of fertility treatment, employing better processes and therapies, the success rate of ART has 
improved, and thus the impetus for using methods that also run the risk of high rates of mul-
tiple pregnancy are no longer warranted or accepted. Now when determining the success of 
an ART technique or an ART service provider, the rate of singleton, term, live birth should be 
seen as the gold standard of measurement and the aim of successful treatment [2]. Strategies 
to achieve this are now the cornerstone in research, development and guidelines in ART tech-
niques and stricter regulations and protocols are in place to implement safer methods.
This chapter will explore ways in which ART, in particular ovulation induction, super-ovulation 
and intra-uterine insemination (IUI) and in-vitro fertilisation (IVF), can be delivered to ensure 
low rates of multiple pregnancy and make ART and the pregnancy that results safer for mother 
and baby.
2. Ovulation induction
Ovulation induction involves stimulating the ovary with the aim to induce mono-follicular-
ovulation in a sub-fertile woman who is anovulatory. A trigger injection, to mimic the mid-
cycle luteinising hormone (LH) surge, is given to initiate release of the ovum and timed 
intercourse is advised.
Multiple pregnancy may occur with ovulation induction secondary to unintended over-
stimulation of the ovary and the development of more than one follicle and the release and 
subsequent fertilisation of more than one oocyte. Rates of multiple pregnancy with ovarian 
stimulation depend greatly on the treatment protocol used, but for all methods has been 
approximated at up to 9 times the rate of natural conception in fertile women [3].
A recent 5-year review of multiple pregnancy rates in the United States revealed 22% of the 
nation’s twin pregnancies were due to ovulation induction and 40% of triplet pregnancies were 
as a result of ovulation induction treatment [4]. The rates of multiple pregnancy secondary to 
ovulation induction are falling as better techniques and practices are introduced however, not 
as quickly as is being seen with more invasive ART techniques such as IVF. Stricter controls 
and more stringent regulations are being enforced in many countries towards IVF treatments 
in the hope of stalling the multiple pregnancy rate, however this has not been replicated in 
the field of ovulation induction, as this is often performed outside of large fertility clinics, or 
Multiple Pregnancy - New Challenges48
without strict tracking protocols. Hence it is believed that ovulation induction accounts for up 
to 65% of the world’s higher order multiple pregnancies [5].
Ovulation induction agents are usually divided into oral and injectable agents with the his-
torical belief being that injectable agents, usually recombinant or urinary derived follicular 
stimulating hormone (FSH), being associated with higher rates of both multiple pregnancy 
and ovarian hyper-stimulation syndrome.
2.1. Clomiphene citrate
Clomiphene citrate was until recently the first line fertility treatment for anovulatory women 
undergoing ovulation induction [6]. Clomiphene is a selective oestrogen receptor modulator 
that blocks negative feedback of rising oestrogen levels at the level of the hypothalamus thereby 
resulting in ongoing FSH secretion and follicular development. Clomiphene citrate has his-
torically had rates of multiple pregnancy quoted at 7%, with higher order multiple pregnancies 
rates occurring in less than 1% of confirmed pregnancies. [7] Newer data however suggests that 
multiple pregnancy rates with the use of clomiphene may be as high as 9% and higher order 
multiple pregnancy rates closer to 2%, as often ultrasound monitoring of the stimulated cycles is 
not performed [8]. Clomiphene, unlike other ovulation induction agents, does not have a higher 
rate of multiple pregnancy rates with higher dosing. The anti-oestrogenic properties exhibited 
by clomiphene on both the cervical mucus and endometrial lining with increased dosing have 
a negative impact on the rate of conception and implantation. Hence, although ovulation rates 
may increase, successful pregnancy, including multiple pregnancy, are not necessarily increased. 
Thus, for clomiphene, unlike other ovulation induction agents, simply prescribing lower doses 
of the agent will do little to reduce multiple pregnancy rates.
2.2. Letrozole
Letrozole is an aromatase inhibitor that is now recommended as a first line ovulation induc-
tion agent [6]. It is associated with higher rates of mono-ovulation than clomiphene and thus 
lower rates of multiple pregnancy, at around 3.5% [9], but with overall similar if not higher 
live birth rates [10]. It has a shorter half-life than clomiphene and, unlike clomiphene, during 
treatment endogenous FSH is suppressed by rising oestrogen levels thus reducing the risk 
of multiple follicles developing. Due to the benefit of increased live birth rates and a reduc-
tion in the rates of multiple pregnancy letrozole should be the oral agent for first line use 
in anovulatory women undergoing ovulation induction. However, letrozole must be used 
under informed consent as ovulation induction is not an approved indication for the drug.
2.3. Metformin
Metformin has, over the last few years, been increasingly used for the management of women 
with PCOS, having potential benefits with regard to its metabolic consequences [11] and andro-
genic side-effects [12]. However, with respect to anovulatory infertility as a sole agent the ben-
efit of increasing the chance of a live birth is not clear, other than perhaps as an adjuvant to 
clomiphene citrate in overweight women [13], or as an adjuvant to FSH ovulation induction [14].
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2.4. Follicular stimulation hormone (FSH)
Injectable agents, usually recombinant FSH, have historically been associated with higher 
rates of multiple pregnancy. When first described dosing regimes in the realm of 225 IU of 
FSH were used to induce ovulation in anovulatory women with multiple pregnancy rates of 
around 25% [15]. As greater experience was gained using FSH and with a clear distinction 
being made between dosing for the aim of mono-ovulation in ovulation induction, versus 
ovarian hyper-stimulation for IVF cycles initial dosages fell dramatically. Low dose, step 
up protocols are now the recommended regime with close monitoring to observe response 
[16]. Unlike oral agents that are given for a limited number of days in the early follicular 
phase, FSH can be given for an extended period until follicular development is seen. With this 
method rates of multiple pregnancy can be as low, or lower, than with oral agents and can be 
achieved with higher live birth rates. In countries with good health insurance and state fund-
ing for fertility treatments out of pocket costs to patients are comparable to oral agents and are 
thus often used as a first line treatment due to their increased success rates.
In our unit, after exclusion of other potential infertility factors, we aim to induce mono-ovulation 
with a low dose step up protocol. We start all women on a low dose of gonadotropin, on aver-
age 25 IU FSH, and monitor women with oestrogen levels and ultrasound tracking of develop-
ing follicles. Dosing is increased if no response is seen after 10 days, with dose increments of 
12.5 IU, until a threshold is reached whereby mono-follicular development occurs and the dose 
is not increased further. If more than 2 follicles of 10 mm are noted the cycle is cancelled, and 
in patients under 35 years consideration is given to cancelling with two follicles. Review of our 
data has showed that our rate of multiple pregnancy using this method for ovulation induction 
is below 4% [17]. This is with a cumulative live birth rate of close to 50% over 3 cycles and a cycle 
cancellation rate of around 10%. After 3 cycles the live birth rate per cycle falls significantly as 
the patients with additional reproductive pathology start to make up a greater percentage of 
remaining patients. If after 3 cycles a successful pregnancy has not occurred we give consider-
ation to switching to IVF treatment. This allows a low rate of multiple pregnancy and a close to 
50% rate of successful pregnancy for our patients without exposing them to the increased risk 
of IVF unless it is warranted.
The hallmark of reducing rates of multiple pregnancy with ovulation induction is to closely 
monitor follicular development both with hormone levels and ultrasound tracking to ensure 
only a single dominant follicle, or a maximum of two, will develop and ultimately ovulate. It 
would be assumed that with close monitoring a clinician could predict when a patient was at 
risk of releasing more than one oocyte and could act prudently to avoid conception in such 
cases. Existing guidelines surrounding risk adverse practice in regard to tracking are sparse 
and not overly cautious. The American College of Obstetricians and Gynaecologists (ACOG) 
guideline recommends abandoning an ovulation induction cycle if there are more than 3 fol-
licles measuring more than 15 mm [18]. Studies have shown that follicles as small as 7 mm 
at time of trigger can result in successful ovulation and impact the multiple pregnancy rate, 
although it is generally believed that follicles of 14 mm in size or greater will have a mature 
oocyte [19]. Capping the recommended maximum number of follicles before cancellation of 
the cycle at more than 3 is doing little to reduce the rate of multiple pregnancy and indeed 
risks, not just a multiple pregnancy but a higher order multiple pregnancy.
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More judicious care can be taken to actively avoid multiple pregnancy by ensuring mono-
ovulation by very closely monitoring oestrogen levels and follicular development on ultra-
sound. By cancelling cycles when more than 2 follicles of greater than 10 mm are present 
has been shown to actively reduce multiple pregnancy rates. Oestrogen levels above 600 pg/
mL have been associated with increased rates of multiple pregnancy [20] and higher than 
2000 pg/mL with higher order multiple pregnancy. [21] Using both ultrasound follicle track-
ing and serum oestradiol measurements to carefully track cycles is imperative to minimise 
multiple pregnancy.
As a general rule, younger women, women with a greater antral follicle count or higher anti-
mullerian hormone (AMH) levels are more likely to have a greater response to a lower dose of 
induction agent and thus should be started at a minimum dose on the first cycle and tracked 
accordingly.
All couples should be worked up prior to embarking on ovulation induction to confirm tubal 
patency and adequate semen analysis, and to ensure a more invasive form of ART may not be 
a better first line therapy. The group of women for who ovulation induction is most widely 
used is those with anovulation secondary to poly-cystic ovarian syndrome (PCOS.) This is 
often a group of patients that are of a younger age than the average infertility patient and 
have a high antral follicle count and in reflection of that, often a high AMH. These women 
may also benefit from the additional use of metformin during their stimulation to improve 
outcomes [14]. It is critical that these women are identified as high risk for responding exces-
sively to even small doses of ovulation induction agents and should be started on very low 
doses of ovulation induction agents and very carefully monitored. Being younger also means 
the rate of fecundity per ovulation is high and therefore every effort should be made to aim 
for mono-ovulation.
Options available when development of an excessive number of follicles is observed include 
cancelling the cycle, aspirating the excess follicles or switching to an egg collection and IVF 
cycle. None of these options are ideal for a patient hoping to achieve a pregnancy but need 
to be discussed with the patient before embarking on treatment. Cancellation of the cycle 
can be devastating to the patient from a financial and emotional cost, however a cancelled 
cycle due to hyper-stimulation of the ovary gives valuable information to the practitioner 
for management of the next cycle in regard to dosing and monitoring. Follicular aspiration 
for either reduction in follicle number, or for transfer to an IVF cycle is difficult if it has not 
been discussed as an option pre-treatment, and has ethical implications in regard to informed 
consent for a patient who is now being faced with either cancellation of the cycle or conver-
sion to a more complicated and costly treatment. It is imperative that as part of the consent 
process for ovulation induction the risk of multiple follicle development is discussed and the 
options and recommendations when an excessive number of follicles develop are considered.
Having an absolute maximum cut off of 2 follicles, and for high risk couples one follicle, will 
be a huge step forward in reducing the multiple pregnancy rates with ovulation induction. 
Such an approach has been associated with multiple pregnancy rates below 5% and no higher 
order multiple pregnancies [22]. This compares with rates up to 30% if no intervention is 
made until follicular numbers reach more than three [23]. High risk couples, for whom more 
than one follicle should be the threshold for cancellation include young women undergoing 
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their first few cycles and who have an expected high fecundity per follicle, but also patients 
for whom multiple pregnancy would be particularly dangerous. This includes women with 
an independent risk of pre-term birth and women with underlying medical conditions mak-
ing them more susceptible to the pregnancy complications of multiple pregnancy.
3. Super ovulation and intra-uterine insemination (IUI)
Super ovulation and IUI involves stimulating the ovary with ovulation induction agents with 
the aim to produce two follicles, then with ovulation trigger performing IUI to allow the 
sperm to bypass the cervical environment. It is usually performed in patients with unex-
plained subfertility or mild male factor subfertility. Consequently, the purpose of the treat-
ment is to increase the chance of a successful pregnancy by increasing the number of oocytes 
ovulated and the availability of sperm.
Given it is used in women that are already ovulating, prudent use of ovulation induction 
agents is imperative and careful monitoring of the cycle with ultrasound and oestrogen lev-
els is important, as in ovulation induction, to prevent multiple pregnancy and higher order 
multiple pregnancy. Unlike ovulation induction, where the aim is to produce a single domi-
nant follicle, super-ovulation is aimed at producing two follicles, with well controlled cycles 
accepting up to three follicles, but certainly no more. The reason is in this situation there is 
a potentially as yet unrecognised factor limiting conception, whereas in standard ovulation 
induction treatment for the anovulatory woman, it is only the absence of ovulation that is 
limiting conception, hence when that is overcome the woman should conceive. Once four 
follicles are present there is no increase in the live birth rate, but a significant increase in the 
multiple pregnancy and higher order multiple pregnancy rate [21].
As the aim is to produce more than one follicle the risk of multiple pregnancy is high, higher than 
that is seen with IVF or ovulation induction. Overall rates of multiple pregnancy are around 14% 
in well controlled cycles, involving cancellation when more than three follicles are identified 
[24]. This is higher than is seen with IVF cycles, even in well controlled ovarian hyperstimula-
tion protocols. Like ovulation induction the discussion regarding switching to an IVF treatment 
course, or cancellation of the cycle is required to be had with the patient prior to embarking on 
treatment. Often the decision around opting for IVF, to minimise the risk of a multiple preg-
nancy, or to adopt the cheaper treatment of super ovulation and IUI, but a greater risk of a 
multiple, revolve around the costs to the patient. This situation is unfortunate as the cost to the 
health care system and the family, ultimately, are greater when a multiple pregnancy results.
4. In-vitro fertilisation
In vitro fertilisation resulted in the first live birth in 1978. Since that time the use of IVF tech-
nology has changed dramatically and the increased success and its widespread use to treat 
all manner of subfertility issues has meant currently in Australia 1 in 25 children born are the 
Multiple Pregnancy - New Challenges52
result of an IVF cycle [25]. Like ovulation induction and super ovulation, IVF is associated 
with increased rates of unintended multiple pregnancy, in comparison to spontaneous con-
ception, plus there is also a greater risk of an embryo splitting and resulting in monozygotic 
twinning.
While the key to reducing rates of multiple pregnancy with ovulation induction and super-
ovulation and IUI lies with careful monitoring of the cycle and judicious cancellation of cycles 
when multiple follicles develop, the cornerstone to reducing multiple pregnancy rates in IVF 
treatment is to ensure single embryo transfer is the norm.
As IVF technology has developed and successful live birth rates have increased the need to 
transfer more than one embryo has rapidly declined. There is no significant difference in the 
live birth rate for women aged under 37 years undergoing a single embryo transfer (sET) com-
pared with a double embryo transfer (dET), only an increase in the multiple pregnancy rate 
and subsequent increased pregnancy complication rate [26]. For women aged under 37 years 
the rate of multiple pregnancy with a double embryo transfer is as high as 25% [27], compared 
with less than 6% for women undergoing single embryo transfer [28].
Although implantation rate is not the gold standard by which to measure success of a fertil-
ity treatment, when compared with sET, dET has been reported to be associated with lower 
implantation rates suggesting a deleterious effect on the intrauterine environment when dET 
is employed [29]. This observation is further supported by the increased rates of poor preg-
nancy outcome when dET is performed but only one embryo implants. This scenario is associ-
ated with increased rates of growth restriction and preterm delivery compared with singleton 
pregnancies resulting from a single embryo transfer [30]. A review of the American Society 
for Assisted Reproductive Technology outcomes between 2004 and 2013, of over 180,000 IVF 
cycles concluded that although the live birth rate may increase with a dET, this is substan-
tially out-weighed by the risk of multiple gestations [31]. They demonstrated that for patients 
with favourable prognostic factors; including younger maternal age, transfer of a blastocyst, 
and additional embryos cryopreserved, the gain in the live birth rate from sET to dET was 
approximately 10–15%, however, the multiple birth rate increased from approximately 2% to 
almost 50% for both fresh and frozen embryo transfer cycles.
Single embryo transfer is associated with not just a reduction in multiple pregnancy rates, but 
also a reduction in overall pregnancy complication rates with little effect on the live birth rate 
compared with double or higher number embryo transfer rates [32]. Double embryo transfer 
rates are occasionally recommended or supported when a patient has particular barriers to 
implantation success and thus have a perceived lower rate of risk to multiple pregnancy with 
dET. These may include advanced maternal age, poor embryo quality or multiple previous 
unsuccessful attempts at single embryo transfer.
The barrier to implementing universal single embryo transfer appears to lie in the cost of IVF 
treatment to the patient. In countries or regions where state funded or supported fertility 
treatment exists, the rates of single embryo transfer are far higher. The factor most influenc-
ing the likelihood a patient will undergo a single embryo transfer over a double or greater 
number embryo transfer is whether or not they have health insurance, a greater influencing 
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factor than that of maternal age [33]. In Australia where fertility treatment is subsidised by the 
state and rates of health insurance are high, the rate of single embryo transfer is over 75% and 
reflected in the multiple pregnancy rate from IVF being below 6% [34]. In comparison, in the 
United States sET recorded in the same year was less than 25% [35]. This is also a reflection of 
the strict regulations that exist in Australia governing IVF treatment.
Regulations and policy governing single embryo transfer also exist in many Scandinavian and 
some European countries, such as Belgium, as well as Australia, with reflective low rates of 
multiple pregnancy and high rates of cycle success. The transfer of more than two embryos 
is banned in Australia and double embryo transfer only allowed in the setting of significant 
advanced maternal age or multiple failed attempts at single embryo transfer [36]. In comparison, 
other European countries like Greece, Montenegro and Lithuania have few regulations govern-
ing IVF protocols and treatment and overall data from Europe show rates of double embryo 
transfer well over 50% and rates of transfer of three or more embryos as high as 12.5% [37]. The 
multiple birth rate is reflected in this practice with the multiple birth rate following IVF being 
18.7% in Europe compared with 5.6% in Australia and New Zealand [37]. The multiple birth rate 
following IVF is even higher in the United States at 26.6% [35]. This is despite slightly higher 
rates of double embryo transfer in Europe, however this is thought to reflect the high rate of fetal 
reductions that occur in Europe as a management strategy for multiple pregnancy.
Despite implementing a single embryo transfer an IVF cycle may still result in a multiple 
pregnancy due to monozygotic twinning. Monozygotic twins are at increased risk of sig-
nificant complications including Twin-Twin Transfusion Syndrome (TTTS) and Twin 
Anaemia-Polycythaemia Sequence (TAPS), fetal anomalies and perinatal morbidity. The rate 
of monozygotic twinning is increased in IVF pregnancy by 6 times compared with spontane-
ously conceived pregnancies [38], occurring at a rate of around 2.5% [39]. The reason for this is 
likely multifactorial. Culture media, embryo quality, use of gonadotropins and manipulation 
of the zona pellucida are all thought to play a role in the increased rates of monozygotic twin-
ning following IVF [40].
In natural conception the rate of monozygotic twinning increases with age, likely a reflection 
of egg quality, however the inverse has been seen in pregnancies conceived with IVF. Women 
under 35 are twice as likely to have a monochorionic twin pregnancy following IVF treat-
ment compared with women aged over 35 [41]. The mechanism for this may include the zona 
pellucida experiencing increased thickening with advancing maternal age, resulting in the 
embryo of an older patient being more robust to the manipulation exerted on it during IVF or 
Intracytoplasmic Sperm Injection (ICSI), or during embryo biopsy. This is an important obser-
vation and further supports the argument for single embryo transfer for younger patients 
with a good chance of implantation per embryo transfer. If a patient is at increased risk of 
monozygotic twinning, and has a double embryo transfer the risk of a higher order multiple 
pregnancy, with the added complication of a monozygotic twin pair develops.
The stress that a developing blastocyst and embryo undergoes during an IVF cycle may ration-
alise the increased rates of monozygotic twinning. Monozygotic twin pregnancies are more 
likely in day 5 blastocyst transfer than day 2 or 3 cleavage stage transfer, perhaps reflective of 
the strain that may be put on the embryo the day of transfer. Monozygotic twinning occurs due 
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to the embryo splitting anywhere from Day 4 through to Day 8. Transfer in the middle of this 
time period involves subtle changes to the pH, temperature and nutrient environment that could 
explain the increased rate during blastocyst transfer. The actual mechanics of the transfer may 
also play a role in making the embryo more likely to split. Blastocyst transfer is associated with 
nearly a three times increased chance of embryo splitting and resultant monozygotic twinning 
compared with cleavage stage transfer [42]. This finding has not lead to a change in practice due 
to the significantly greater live birth rate seen overall with blastocyst transfer due to the ability to 
select an embryo that has survived until day 5 of development and also result in transfer at a simi-
lar time to when the blastocyst would be reaching the uterine cavity in a natural conception [43].
The increased rate of monozygotic twinning for blastocyst transfer is not replicated, or at 
least not as pronounced, when the transfer is a result of a frozen cycle, rather than a fresh 
transfer [41]. An explanation for this is the freezing/thawing cycle may harden the zona pel-
lucida making the blastocyst more robust against the process of embryo transfer and reduce 
the chance of splitting. A regime of ‘freeze all’ may be worthwhile to further reduce rates of 
multiple pregnancy from monozygotic twinning with blastocyst transfer.
Micro-manipulation techniques of the egg and embryo such as ICSI and pre-implantation 
genetic diagnosis have long been thought to play a role in increased rates of monozygotic 
twinning through weakening of the zona pellucida making it prone to splitting. Like blasto-
cyst transfer, if this effect exists, it is likely associated with fresh transfers rather than frozen 
transfers. Because of this it is recommended that conventional IVF be used over ICSI unless 
significant male factor fertility issues exist.
Embryo quality has an association with the chance of monozygotic twinning. Poorer embryo 
quality has been shown to increase the rate of monozygotic twinning [44]. An appreciation of 
this is important when considering double embryo transfer due to poorer embryo quality. An 
awareness that the resultant pregnancy may develop into a higher order pregnancy, such as a 
dichorionic-triamniotic triplet pregnancy is crucial.
Not all multiple pregnancies that develop after single embryo transfers are monozygotic. A 
review of twin pregnancies following single embryo transfer found 18% of twin pregnancies 
were dizygotic [45]. The explanation for this was likely concurrent spontaneous conception 
with a frozen transfer or ovulation of uncollected eggs and subsequent fertilisation with 
fresh transfers. This hypothesis is supported by the fact that unexplained subfertility, with 
an underlying chance of conception, and obesity, that increases chance of uncollected oocytes 
due to limitations of ultrasound, was the main risk factors for dizygotic twinning in this sce-
nario. The importance of abstaining from unprotected sexual intercourse at time of transfer is 
imperative when counselling couples on how to reduce the risk of multiple pregnancy.
5. Conclusion
The rate of multiple pregnancy associated with ART has fallen steadily with the implemen-
tations of better practices. As pregnancy success rates have increased the belief that more 
follicles or more embryos equates to better outcomes has been disproven. Close monitoring of 
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ovulation stimulation protocols, and a practice of single embryo transfer for IVF has resulted 
in far lower multiple pregnancy rates and safer practices for women. An awareness of the risk 
of multiple pregnancy with ART and the ways in which this can be avoided is paramount to 
the future direction of ART, both for research and regulatory bodies.
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